Bergapten may reduce bone loss by blocking signals that increase bone breakdown cells and osteoporosis after ovary removal

Bergapten treatment showed beneficial effects on ovariectomy-induced osteoporosis in vivo.

• Bergapten reduced osteoclast formation in bone marrow macrophages and RAW264.7 cells without causing cell damage.
• The treatment inhibited specific signaling pathways, including NF-κB and JNK, while not affecting p38 and ERK.
• Bergapten decreased the levels of key transcription factors NFATc1 and c-fos, which are associated with osteoclast differentiation.
• It disrupted the formation of structures necessary for bone resorption, impairing osteoclast activity.

Simplified